Treatment strategies for chronic hepatitis C: Update since the 1997 national institutes of health consensus development Conference

Journal of Gastroenterology and Hepatology (Australia)

Volumn 14, Issue SUPPL., 1999, Pages

  Ahmed, Aijaz ^a   Keeffe, Emmet B ^a,b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Chronic hepatitis C; Hepatitis C; Treatment of chronic hepatitis C

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA2B INTERFERON PLUS RIBAVIRIN; ALPHAN1 INTERFERON; AMANTADINE; ANTIVIRUS AGENT; CONSENSUS INTERFERON; INTERFERON; PROTEINASE INHIBITOR; REBETRON; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN; UNCLASSIFIED DRUG; URSODEOXYCHOLIC ACID;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL ACTIVITY; ARTICLE; DEPRESSION; DISEASE COURSE; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG RESPONSE; DRUG SAFETY; FATIGUE; HEPATITIS C; HISTOLOGY; HUMAN; LIVER BIOPSY; PRIORITY JOURNAL; TREATMENT INDICATION; VIRUS LOAD;

EID: 0032976179     PISSN: 08159319     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1746.1999.01875.x     Document Type: Article

References (49)

1. Di Bisceglie AM. Hepatitis C. Lancet 1998; 351: 351-5.
2. Tong MJ, El-Farra NS, Reikes AR, Co RL. Clinical outcomes after transfusion-associated hepatitis C. N. Engl. J. Med. 1995; 332: 1463-6.
3. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR and DOSVIRC groups. Lancet 1998; 349: 825-32.
4. Alter MJ. Epidemiology of hepatitis C. Hepatology 1997; 26 (Suppl. 1): S62-5.
5. Gretch DR. Diagnostic tests for hepatitis C. Hepatology 1997; 26 (Suppl. 1): S43-7.
6. Baron S, Coppenhaver DH, Dianzani F et al. Introduction to the interferon system. In: Baron S, Coppenhaver DH, Dianzani F et al eds. Interferons: Principles and Medical Applications. Galveston: The University of Texas, 1992; 1-15.
7. Carithers Jr RL, Emerson SS. Therapy of hepatitis C. Meta-analysis of interferon alfa-2b trials. Hepatology 1997; 26 (Suppl. 1): S83-8.
8. Lee WM. Therapy of hepatitis C. Interferon alfa-2a trials. Hepatology 1997; 26 (Suppl. 1): S89-95.
9. Farrell GC. Therapy of hepatitis C. Interferon alfa-nl trials. Hepatology 1997; 26 (Suppl. 1): S96-100.
10. Keeffe FB, Hollinger FB, Consensus Interferon Study Group. Therapy of hepatitis C. Consensus interferon trials. Hepatology 1997; 26 (Suppl. 1): S101-7.
11. National Institute of Health Consensus Development Conference Panel Statement. Management of hepatitis C. Hepatology 1997; 26 (Suppl. 1): S2-10.
12. Davis GL, Lau JYN. Factors predictive of a beneficial response to therapy of hepatitis C. Hepatology 1997; 26 (Suppl. 1): S122-7.
13. Lindsay KL. Therapy of hepatitis C. Overview. Hepatology 1997; 26 (Suppl. 1): S71-7.
14. Gretch DR, Rosa CD, Corcy L, Carithers RL. Assessment of hepatitis C viremia using molecular amplification tech-nologies. Viral Hepat. Rev. 1996; 2: 85-96.
15. Knodell RG, Ishak KG, Black WC et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1: 431-5.
16. Marcellin P, Boyer N, Gervais A et al. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy. Ann. Intern. Med. 1997; 127: 875-81.
17. Bennett WG, Inoue Y, Beck JR, Wong JB, Pauker SG, Davis GL. Cost-effectiveness of a single course of interferon alfa-2b in patients with histologically mild chronic hepatitis C. Ann. Intern. Med. 1997; 127: 855-65.
18. Bardelli F, Messori A, Rampazzo R, Alberti A, Martini N. Effect of recombinant or lymphoblastoid interferon-alpha on alanine aminotransferase in patients with chronic hepatitis C or chronic non-A non-B hepatitis. A meta-analysis. Clin. Drug Invest. 1995; 9: 239-54.
19. Bacon BR, Farrell G, Benhamou JP et al. Lymphoblastoid interferon improves long-term response to a six month course of treatment when compared with recombinant interferon alfa2b (Abstract). Hepatology 1995; 22: 152A.
20. Farrell G, Bacon B, Goldin R, The Clinical Advisory Group for the Hepatitis C Comparative Study. Final results of an international controlled trial comparing lymphoblastoid interferon-α nl with recombinant interferon-α 2b in chronic hepatitis C (HCV) (Abstract). J. Hepatol. 1997; 26: 83.
21. Poynard T, Leroy V, Cohard M et al. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C. Effects of dose and duration. Hepatology 1996; 24: 778-89.
22. Benhamou JP, Hopf U, Rizzetto M, Sanchez-Tapiar JM, Braconier JH, Buhler H. A randomised, double-blind, controlled, multicentre trial of human lymphoblastoid interferon alpha in the treatment of adults with chronic hepatitis non-A, non-B (C) (Abstract). J. Hepatol. 1995; 21: 173A.
23. Lindsay KL, Davis GL, Schiff ER et al. Response to higher doses of interferon alfa-2b in patients with chronic hepatitis C. A randomized multicenter trial. Hepatology 1996; 24: 1034-40.
24. Chemello L, Bonetti P, Cavalletto L et al. Randomized trial comparing three different regimens of alpha-2a-interferon for chronic hepatitis C. The TriVeneto Viral Hepatitis Group. Hepatology 1995; 22: 700-6.
25. Rumi M, Del Ninno E, Parravicini ML et al. A prospective, randomized trial comparing lymphoblastoid to recomhinant interferon alfa 2a as therapy for chronic hepatitis C. Hepatology 1996; 24: 1366-70.
26. Seeff LB, Buskell-Bales Z, Wright EC et al. Long-term mortality after transfusion-associated non-A, non-B hepatitis. N. Engl. J. Med. 1992; 327: 1906-11.
27. Crowe J, Doyle C, Fielding JF et al. Presentation of hepatitis C in a unique uniform cohort 17 years from inoculation (Abstract). Gastroenterology 1995; 108: 1054A.
28. Marcellin P, Levy S, Erlinger S. Therapy of hepatitis C. Patients with normal aminotransferase levels. Hepatology 1997; 26 (Suppl. 1): S133-6.
29. Alberti A, Chemello L, Noventa F, Cavalletto L, De Salvo G. Therapy of hepatitis C. Re-treatment with alpha interfcron. Hepatology 1997; 26 (Suppl. 1): S137-42.
30. Fattovich G, Giustina G, Favarato S, Ruol A, Investigators of the Italian Association for the Study of the Liver. A survey of adverse events in 11 241 patients with chronic viral hepatitis treated with alfa interferon. J. Hepatol. 1996; 24: 38-47.
31. Dusheiko G. Side effects of alpha interferon in chronic-hepatitis C. Hepatology 1997, 26 (Suppl. 1): S112-21.
32. Balistreri WF. Treatment of chronic hepatitis C in children. Viral Hepatitis Rev. 1995; 1: 121-8.
33. Araya V, Rakela J, Wright T. Hepatitis C after orthotopic liver transplantation. Gastroenterology 1997; 112: 575-82.
34. Rosen HR, Friedman LS, Martin P. Hepatitis C in renal dialysis and transplant patients. Viral Hepatitis Rev. 1996; 2: 97-110.
35. Garcia G, Terrault N, Wright TL. Hepatitis C virus infection in the immunocompromised patient. Semin. Gastrointest. Dis. 1995; 6: 35-15.
36. Wilson RA. Extrahepatic manifestations of chronic viral hepatitis. Am. J. Gastroenterol. 1997; 92: 4-17.
37. Schapiro GD, Friedman LS. Autoimmune hepatitis and/or hepatitis C. How to decide. Hepatology 1996; 23: 647-9.
38. Bellary S, Schiano T, Hartman G, Black M. Chronic hepatitis with combined features of autoimmune chronic hepatitis and chronic hepatitis C. Favorable response to prednisone and azathioprine. Ann. Intern. Med. 1995; 123: 32-4.
39. Schalm SW, Fattovich G, Brouwer JT. Therapy of hepatitis C. Patients with cirrhosis. Hepatology 1997; 26 (Suppl. 1): S12H-32.
40. Karino Y, Toyota J, Sugawara M et al. Early loss of serum hepatitis C virus RNA can predict a sustained response to interferon therapy in patients with chronic hepatitis C. Am. J. Gastroenterol. 1997; 92: 61-5.
41. Hoofnagle JH, Mullen KD, Jones DB et al. Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon: A preliminary report. N. Engl. J. Med. 1986; 315: 1575-8.
42. Lamb NP, Neumann AU, Gretch DR. Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa. Hepatology 1997; 26: 226-31.
43. Reichard O, Schvarcz R, Weiland O. Therapy of hepatitis C. Alpha interferon and ribavirin. Hepatology 1997; 26 (Suppl. 1): S108-11.
44. Reichard O, Norkrans G, Fryden A et al. Randomised, double-blind, placebo-controlled trial of interferon alfa-2b with and without ribavirin for chronic hepatitis C. Lancet 1998; 351: 83-7.
45. Davis GL, Esteban-Mur R, Rustgi V et al. Re-treatment of relapse after interferon therapy for chronic hepatitis C. An international randomized controlled trial of interferon plus ribavirin versus interferon alone (Abstract). Hepatology 1997; 26: 247A.
46. Bonkovsky HL. Therapy of hepatitis C. Other options. Hepatology 1997; 26 (Suppl. 1): S143-51.
47. Smith JP. Therapy of chronic hepatitis C with amantadine. Dig. Dis. Sci. 1997; 42: 1681-7.
48. Camma C, Di Marco V, Lo Iacono O et al. Long-term course of interferon-treated chronic hepatitis C. J. Hepatol. 1998; 28: 531-7.
49. Kasahara A, Hayashi N, Mochizuki K et al. Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Hepatology 1998; 27: 1394-402.